Literature DB >> 9302904

Middle ear gas composition in pathologic conditions: mass spectrometry in otitis media with effusion and atelectasis.

L Hergils1, B Magnuson.   

Abstract

It is generally assumed that the gas enclosed in the middle ear and mastoid air cell system is subject to continuous absorption, and that partial pressures for oxygen and carbon dioxide equal those of "mixed venous blood." We previously determined the concentrations in 10 adults with healthy ears by means of mass spectrometry. The results showed that the value for oxygen was in the expected range, but that the value for carbon dioxide was higher than in "mixed venous blood." The aim of the present investigation was to measure the gas concentrations with the same technique in diseased ears, to see if there are any differences in middle ear gases between healthy and diseased ears. In terms of group means, the present measurements in 13 ears of children with otitis media with effusion or atelectasis did not differ from the values previously obtained for healthy ears of adults for any of the gases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9302904     DOI: 10.1177/000348949710600905

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  11 in total

1.  Study of the auditory tube by ventilation scintigraphy with technetium-99m.

Authors:  Andrei P Timoshenko; Christian Denis; Francis Dubois; Christian Martin; Jean-Michel Prades
Journal:  Surg Radiol Anat       Date:  2005-10-07       Impact factor: 1.246

2.  Oral pseudoephedrine decreases the rate of transmucosal nitrous oxide exchange for the middle ear.

Authors:  Miriam S Teixeira; Cuneyt M Alper; Brian S Martin; Brendan M Cullen Doyle; William J Doyle
Journal:  Laryngoscope       Date:  2015-07-07       Impact factor: 3.325

3.  The mastoid as a functional rate-limiter of middle ear pressure change.

Authors:  William J Doyle
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2006-12-15       Impact factor: 1.675

4.  A formal description of middle ear pressure-regulation.

Authors:  William J Doyle
Journal:  Hear Res       Date:  2017-08-24       Impact factor: 3.208

5.  Histamine Applied Topically to the Nasal Mucosa Increases the Transmucosal Nitrous Oxide Exchange for the Middle Ear.

Authors:  Miriam S Teixeira; Cuneyt M Alper; Brian S Martin; Selma Cetin; Jenna A El-Wagaa; William J Doyle
Journal:  Ann Otol Rhinol Laryngol       Date:  2017-01-19       Impact factor: 1.547

6.  Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates of Streptococcus pneumoniae.

Authors:  J N Weiser; D Bae; H Epino; S B Gordon; M Kapoor; L A Zenewicz; M Shchepetov
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

7.  Directional asymmetry in the measured nitrous oxide time constant for middle ear transmucosal gas exchange.

Authors:  William J Doyle; Sancak Yuksel; Juliane Banks; Cuneyt M Alper
Journal:  Ann Otol Rhinol Laryngol       Date:  2007-01       Impact factor: 1.547

8.  Oxymetazoline Applied Topically to the Nasal Mucosa Decreases Trans-Mucosal Nitrous Oxide Exchange for the Middle Ear.

Authors:  Miriam S Teixeira; Cuneyt M Alper; Brian S Martin; Narmin Helal; Brendan M Cullen Doyle; William J Doyle
Journal:  Ann Otol Rhinol Laryngol       Date:  2015-11-26       Impact factor: 1.547

9.  HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants.

Authors:  Michael T Cheeseman; Hayley E Tyrer; Debbie Williams; Tertius A Hough; Paras Pathak; Maria R Romero; Helen Hilton; Sulzhan Bali; Andrew Parker; Lucie Vizor; Tom Purnell; Kate Vowell; Sara Wells; Mahmood F Bhutta; Paul K Potter; Steve D M Brown
Journal:  PLoS Genet       Date:  2011-10-20       Impact factor: 5.917

10.  Variation of growth characteristics of pneumococcus with environmental conditions.

Authors:  Adrienn Tóthpál; Katherine Desobry; Shreyas S Joshi; Anne L Wyllie; Daniel M Weinberger
Journal:  BMC Microbiol       Date:  2019-12-26       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.